- Auteur(s) : Élodie Vauleon, Habiba Mesbah, Daniel Gedouin, Isabelle Lecouillard, Guillaume Louvel, Abderrahmane Hamlat, Laurent Riffaud, Béatrice Carsin, Véronique Quillien, Odile Audrain, Thierry Lesimple
- Mots-clés : glioblastoma, recurrence, bevacizumab, irinotecan
- Page(s) : 121-6
- DOI : 10.1684/bdc.2011.1528
- Année de parution : 2012
Résumé : Despite progress in the initial management of glioblastoma (GB), the vast majority of patients will experience recurrence within 2-3 years. The medical treatment of these recurrences is being modified by the use of antiangiogenic therapies. Twenty-four patients, who relapsed from GB after chemoradiation followed by adjuvant temozolomide in Rennes, were treated by conventional chemotherapy (nitrosourea) or by the combination of irinotecan and bevacizumab. In this retrospective analysis, overall survival from diagnosis of recurrence was significantly longer in patients treated with the combination of bevacizumab and irinotecan than with nitrosourea (5 months
versus 11,5 months). The combination of irinotecan and bevacizumab appeared to provide clinical benefit to patients with recurrent GB.